6602-32-0Relevant articles and documents
Preparation method of 2-bromo-3-methoxypyridine
-
Paragraph 0014-0015; 0017-0018; 0021-0022, (2020/02/14)
The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of 2-bromine-3-methoxypyridine, which comprises the following reaction steps: (1) preparation of 2-bromine-3-hydroxypyridine, and (2) preparation of 2-bromine-3-methoxypyridine: cooling the sodium hydroxide aqueous solution to -10 DEG C to 0 DEG C by using an ice salt bath, and dropwise adding liquid bromine within the temperature range, dissolving 3-hydroxypyridine in a sodium hydroxide aqueous solution, dropwise adding the solution into the liquid bromine solution, and keepingthe system temperature at 10-15 DEG C, after dropwise adding, stirring the mixed solution for 2.5-3 hours at room temperature, and then adjusting the pH value to 7 by using acid; and recrystallizing the obtained crude product to obtain the 2-bromo-3-hydroxypyridine. The method has the beneficial effects of mild reaction conditions, short route and high yield.
Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase
Hu, Qingzhong,Kunde, Jessica,Hanke, Nina,Hartmann, Rolf W.
supporting information, p. 139 - 150 (2015/04/22)
The inhibition of 11β-hydroxylase is a promising strategy for the treatment of Cushing's syndrome, in particular for the recurrent and subclinical cases. To achieve proof of concept in rats, efforts were paid to identify novel lead compounds inhibiting both human and rat CYP11B1. Modifications on a potent promiscuous inhibitor of hCYP11B1, hCYP11B2 and hCYP19 (compound IV) that exhibited moderate rCYP11B1 inhibition led to compound 8 as a new promising lead compound. Significant improvements compared to starting point IV were achieved regarding inhibitory potency against both human and rat CYP11B1 (IC50 values of 2 and 163 nM, respectively) as well as selectivity over hCYP19 (IC50 Combining double low line 1900 nM). Accordingly, compound 8 was around 7-and 28-fold more potent than metyrapone regarding the inhibition of human and rat CYP11B1 and exhibited a comparable selectivity over hCYP11B2 (SF of 3.5 vs 4.9). With further optimizations on this new lead compound 8, drug candidates with satisfying profiles are expected to be discovered.
Synthesis of the phenylpyridal scaffold as a helical peptide mimetic
Bourne, Gregory T.,Kuster, Daniel J.,Marshall, Garland R.
supporting information; experimental part, p. 8439 - 8445 (2010/09/08)
Phenylpyridal- and phenyldipyridal-based scaffolds have been designed and synthesized as novel helical peptide mimetics. The synthesis required optimisation and selective alkylation in producing 2,6-functionalized 3-hydroxypyridine derivatives for a convergent scheme. The pyridine analogues were coupled by a series of Suzuki/Stille types cross-coupling reactions. A series of biaryl and ter-aryl substituted heterocycles were produced. The synthetic approach was concise and high yielding allowing large variability at the wanted sidechain attachment points. A number of compounds were synthesised to show the versatility of the strategy.
